BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 24803843)

  • 1. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
    Meola G
    Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
    Meola G; Cardani R
    Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myotonic dystrophies: molecular, clinical, and therapeutic challenges.
    Udd B; Krahe R
    Lancet Neurol; 2012 Oct; 11(10):891-905. PubMed ID: 22995693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.
    Kamsteeg EJ; Kress W; Catalli C; Hertz JM; Witsch-Baumgartner M; Buckley MF; van Engelen BG; Schwartz M; Scheffer H
    Eur J Hum Genet; 2012 Dec; 20(12):1203-8. PubMed ID: 22643181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
    Meola G; Cardani R
    Neurol Sci; 2017 Apr; 38(4):535-546. PubMed ID: 28078562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myotonic dystrophies: clinical presentation, pathogenesis, diagnostics and therapy].
    Finsterer J; Rudnik-Schöneborn S
    Fortschr Neurol Psychiatr; 2015 Jan; 83(1):9-17. PubMed ID: 25602187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.
    Meola G; Cardani R
    J Neuromuscul Dis; 2015 Jul; 2(s2):S59-S71. PubMed ID: 27858759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of muscle atrophy in myotonic dystrophies.
    Timchenko L
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
    Ranum LP; Day JW
    Curr Neurol Neurosci Rep; 2002 Sep; 2(5):465-70. PubMed ID: 12169228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.
    Bachinski LL; Udd B; Meola G; Sansone V; Bassez G; Eymard B; Thornton CA; Moxley RT; Harper PS; Rogers MT; Jurkat-Rott K; Lehmann-Horn F; Wieser T; Gamez J; Navarro C; Bottani A; Kohler A; Shriver MD; Sallinen R; Wessman M; Zhang S; Wright FA; Krahe R
    Am J Hum Genet; 2003 Oct; 73(4):835-48. PubMed ID: 12970845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24.
    Le Ber I; Martinez M; Campion D; Laquerrière A; Bétard C; Bassez G; Girard C; Saugier-Veber P; Raux G; Sergeant N; Magnier P; Maisonobe T; Eymard B; Duyckaerts C; Delacourte A; Frebourg T; Hannequin D
    Brain; 2004 Sep; 127(Pt 9):1979-92. PubMed ID: 15215218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
    Timchenko L
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myotonic dystrophy type 2 and related myotonic disorders.
    Meola G; Moxley RT
    J Neurol; 2004 Oct; 251(10):1173-82. PubMed ID: 15503094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myotonic dystrophy - a new insight into a well-known disease].
    Lusakowska A; Sułek-Piatkowska A
    Neurol Neurochir Pol; 2010; 44(3):264-76. PubMed ID: 20625963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
    Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
    Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.
    Meola G; Biasini F; Valaperta R; Costa E; Cardani R
    J Neurol; 2017 Aug; 264(8):1705-1714. PubMed ID: 28550479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (CCUG)
    Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A
    Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2.
    Valaperta R; Lombardi F; Cardani R; Fossati B; Brigonzi E; Merli I; Sansone V; Merletti G; Spina E; Meola G; Costa E
    Genet Test Mol Biomarkers; 2015 Dec; 19(12):703-9. PubMed ID: 26505324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myotonic dystrophies type 1 and 2: anesthetic care.
    Veyckemans F; Scholtes JL
    Paediatr Anaesth; 2013 Sep; 23(9):794-803. PubMed ID: 23384336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.